EcoDrugPlus

Integrin Beta-3

Ensembl ID : ENSLCAG00010022030
Gene Symbol: LOC108872765
4 Cross references
201 Possible Orthologues:

Integrin Subunit Alpha 4

Ensembl ID : ENSLCAG00010011473
Gene Symbol: ITGA4
1 Cross references
225 Possible Orthologues:

Integrin Subunit Alpha 5

Ensembl ID : ENSLCAG00010023353
Gene Symbol: ITGA5
2 Cross references
197 Possible Orthologues:

Integrin Subunit Beta 6

Ensembl ID : ENSLCAG00010008054
Gene Symbol: ITGB6
4 Cross references
205 Possible Orthologues:

Integrin Subunit Beta 8

Ensembl ID : ENSLCAG00010019908
Gene Symbol: ITGB8
1 Cross references
202 Possible Orthologues:

Integrin, Alpha 5 (Fibronectin Receptor, Alpha Polypeptide)

Ensembl ID : ENSLCAG00010023411
Gene Symbol: ITGA5
4 Cross references
206 Possible Orthologues:

Integrin, Alpha V

Ensembl ID : ENSLCAG00010019066
Gene Symbol: ITGAV
4 Cross references
237 Possible Orthologues:

Integrin, Beta 1a

Ensembl ID : ENSLCAG00010027758
Gene Symbol: ITGB1A
4 Cross references
213 Possible Orthologues:

Integrin, Beta 5

Ensembl ID : ENSLCAG00010020389
Gene Symbol: LOC108902467
4 Cross references
205 Possible Orthologues:

Interleukin-1 Receptor-Associated Kinase 4

Ensembl ID : ENSLCAG00010023870
Gene Symbol: LOC108888551
4 Cross references
202 Possible Orthologues:

Interleukin-6

Ensembl ID : ENSLCAG00010006533
Gene Symbol: LOC108897837
3 Cross references
162 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 1

Ensembl ID : ENSLCAG00010008801
Gene Symbol: LOC108902499
4 Cross references
234 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).